• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
CROI 2024: Acute and Post-Acute COVID-19.2024年逆转录病毒和机会性感染会议:急性及急性后新冠病毒感染
Top Antivir Med. 2024 Aug 12;32(4):523-541.
2
CROI 2023: Acute and Post-Acute COVID-19.CROI 2023:急性和新冠感染后 COVID-19。
Top Antivir Med. 2023 May;31(3):493-509.
3
The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody.评估在接受抗 CD20 抗体治疗的 B 细胞淋巴瘤 COVID-19 患者中,使用抗 SARS-CoV-2 单克隆抗体和长期使用抗病毒药物期间,病毒持续脱落的风险因素。
BMC Infect Dis. 2024 Jul 22;24(1):715. doi: 10.1186/s12879-024-09631-3.
4
Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values.利妥昔单抗治疗后持续的严重急性呼吸综合征冠状病毒 2 感染:临床过程和治疗干预反应与定量病毒培养和循环阈值相关。
Antimicrob Resist Infect Control. 2022 Feb 5;11(1):28. doi: 10.1186/s13756-022-01067-1.
5
Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.免疫功能低下宿主持续性 SARS-CoV-2 感染的晚期抗病毒治疗效果。
J Virol. 2024 Sep 17;98(9):e0090524. doi: 10.1128/jvi.00905-24. Epub 2024 Aug 29.
6
Vaccine and antiviral drug promise for preventing post-acute sequelae of COVID-19, and their combination for its treatment.疫苗和抗病毒药物有望预防 COVID-19 的后遗症,它们的联合应用有望治疗 COVID-19。
Front Immunol. 2024 Aug 9;15:1329162. doi: 10.3389/fimmu.2024.1329162. eCollection 2024.
7
SARS-CoV-2 humoral immunity in people living with HIV-1.SARS-CoV-2 体液免疫与人类免疫缺陷病毒 1 共存者。
Trends Immunol. 2024 Jul;45(7):511-522. doi: 10.1016/j.it.2024.05.005. Epub 2024 Jun 17.
8
Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations.免疫功能正常和免疫功能低下的癌症患者接种 SARS-CoV-2 疫苗后的体液和细胞免疫反应。
Microbiol Spectr. 2024 Mar 5;12(3):e0205023. doi: 10.1128/spectrum.02050-23. Epub 2024 Feb 14.
9
Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections.接种疫苗后 SARS-CoV-2 感染的 6 个月后遗症:10024 例突破感染的回顾性队列研究。
Brain Behav Immun. 2022 Jul;103:154-162. doi: 10.1016/j.bbi.2022.04.013. Epub 2022 Apr 18.
10
Inflammation, immunity, and antigen persistence in post-acute sequelae of SARS-CoV-2 infectionImmunity and inflammaion in post-acute sequelae of SARS-CoV-2 infection.新型冠状病毒感染后急性后遗症中的炎症、免疫和抗原持续存在。 新型冠状病毒感染后急性后遗症中的免疫与炎症。
Curr Opin Immunol. 2022 Aug;77:102228. doi: 10.1016/j.coi.2022.102228. Epub 2022 May 24.

本文引用的文献

1
Plasma-based antigen persistence in the post-acute phase of COVID-19.新冠病毒感染后急性期血浆中抗原的持续存在情况。
Lancet Infect Dis. 2024 Jun;24(6):e345-e347. doi: 10.1016/S1473-3099(24)00211-1. Epub 2024 Apr 8.
2
Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.奈玛特韦片/利托那韦片组合包装用于新冠病毒感染的成年门诊患者(接种或未接种疫苗)。
N Engl J Med. 2024 Apr 4;390(13):1186-1195. doi: 10.1056/NEJMoa2309003.
3
Prevalence of persistent SARS-CoV-2 in a large community surveillance study.大型社区监测研究中 SARS-CoV-2 的持续流行率。
Nature. 2024 Feb;626(8001):1094-1101. doi: 10.1038/s41586-024-07029-4. Epub 2024 Feb 21.
4
Associations between post-acute sequelae of SARS-CoV-2, COVID-19 vaccination and HIV infection: a United States cohort study.新型冠状病毒2型(SARS-CoV-2)感染的急性后遗症、新冠病毒病(COVID-19)疫苗接种与人类免疫缺陷病毒(HIV)感染之间的关联:一项美国队列研究
Front Immunol. 2024 Jan 22;15:1297195. doi: 10.3389/fimmu.2024.1297195. eCollection 2024.
5
Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2.长新冠表现为 T 细胞失调、炎症和对 SARS-CoV-2 的不协调适应性免疫反应。
Nat Immunol. 2024 Feb;25(2):218-225. doi: 10.1038/s41590-023-01724-6. Epub 2024 Jan 11.
6
A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial.用于香港新冠后综合征的共生制剂(SIM01)的随机、双盲、安慰剂对照试验(RECOVERY)。
Lancet Infect Dis. 2024 Mar;24(3):256-265. doi: 10.1016/S1473-3099(23)00685-0. Epub 2023 Dec 7.
7
Rapid cloning-free mutagenesis of new SARS-CoV-2 variants using a novel reverse genetics platform.新型冠状病毒突变体的快速无克隆诱变:使用一种新型反向遗传学平台。
Elife. 2023 Nov 21;12:RP89035. doi: 10.7554/eLife.89035.
8
Self-Reported Neuropsychiatric Post-COVID-19 Condition and CSF Markers of Neuroinflammation.自我报告的新冠后神经精神状况与神经炎症的脑脊液标志物
JAMA Netw Open. 2023 Nov 1;6(11):e2342741. doi: 10.1001/jamanetworkopen.2023.42741.
9
Serotonin reduction in post-acute sequelae of viral infection.病毒感染后急性后遗症中的血清素减少。
Cell. 2023 Oct 26;186(22):4851-4867.e20. doi: 10.1016/j.cell.2023.09.013. Epub 2023 Oct 16.
10
Distinguishing features of long COVID identified through immune profiling.通过免疫分析鉴定出长新冠的特征。
Nature. 2023 Nov;623(7985):139-148. doi: 10.1038/s41586-023-06651-y. Epub 2023 Sep 25.

2024年逆转录病毒和机会性感染会议:急性及急性后新冠病毒感染

CROI 2024: Acute and Post-Acute COVID-19.

作者信息

Antar Annukka A R, Peluso Michael J

机构信息

Johns Hopkins University, Baltimore, Maryland, USA.

University of California San Francisco, San Francisco, USA.

出版信息

Top Antivir Med. 2024 Aug 12;32(4):523-541.

PMID:39746673
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11361755/
Abstract

Studies of acute and post-acute COVID-19, including their biology, prevention, and treatment, were presented at the 2024 Conference on Retroviruses and Opportunistic Infections. Numerous studies reported on the impact of hybrid immunity (ie, from a combination of prior infection and vaccination) on the natural history, pathogenesis, and outcomes of infection with modern SARS-CoV-2 variants. Several studies demonstrated the continued benefit of SARS-CoV-2 vaccination and the effect of treatment, particularly in the setting of severe disease. New data regarding persistent RNA shedding in immunocompromised populations were presented, demonstrating the potential challenges that this phenomenon poses with regard to viral evolution. In addition, there was a continued focus\ on post-acute sequelae of SARS-CoV-2 including its clinical manifestations and potential underlying biology. These and other studies are summarized here.

摘要

关于急性和急性后新冠病毒感染(包括其生物学特性、预防和治疗)的研究在2024年逆转录病毒与机会性感染会议上进行了展示。众多研究报告了混合免疫(即既往感染和疫苗接种相结合)对感染现代新冠病毒变异株的自然史、发病机制和感染结局的影响。多项研究证明了新冠病毒疫苗接种的持续益处以及治疗效果,尤其是在重症疾病情况下。会上展示了关于免疫功能低下人群中持续RNA脱落的新数据,证明了这一现象在病毒进化方面带来的潜在挑战。此外,人们继续关注新冠病毒的急性后后遗症,包括其临床表现和潜在的生物学基础。以下总结了这些及其他研究。